Clearbridge Investments LLC Has $361,000 Stock Position in Boston Scientific Co. (NYSE:BSX)

Clearbridge Investments LLC lifted its position in Boston Scientific Co. (NYSE:BSX) by 14.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,237 shares of the medical equipment provider’s stock after buying an additional 767 shares during the quarter. Clearbridge Investments LLC’s holdings in Boston Scientific were worth $361,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Bruce G. Allen Investments LLC acquired a new position in Boston Scientific during the 4th quarter valued at $28,000. Motco raised its stake in Boston Scientific by 136.3% during the 3rd quarter. Motco now owns 645 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 372 shares during the last quarter. Venturi Wealth Management LLC raised its stake in Boston Scientific by 58.0% during the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 215 shares during the last quarter. Asset Dedication LLC raised its stake in Boston Scientific by 42.6% during the 3rd quarter. Asset Dedication LLC now owns 786 shares of the medical equipment provider’s stock valued at $41,000 after purchasing an additional 235 shares during the last quarter. Finally, Cetera Trust Company N.A acquired a new position in Boston Scientific during the 4th quarter valued at $43,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Evercore ISI upped their target price on shares of Boston Scientific from $72.00 to $78.00 and gave the company an “outperform” rating in a research note on Thursday, April 25th. Wells Fargo & Company upped their target price on shares of Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. StockNews.com upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Thursday. TD Cowen boosted their price target on shares of Boston Scientific from $65.00 to $77.00 and gave the company an “outperform” rating in a report on Thursday, March 7th. Finally, Mizuho boosted their price target on shares of Boston Scientific from $85.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, May 15th. Two equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $75.41.

Boston Scientific Stock Up 1.7 %

Shares of NYSE:BSX opened at $75.63 on Monday. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $76.25. The company’s 50-day moving average price is $70.61 and its two-hundred day moving average price is $63.86. The company has a quick ratio of 1.14, a current ratio of 1.66 and a debt-to-equity ratio of 0.47. The firm has a market cap of $110.96 billion, a P/E ratio of 63.55, a P/E/G ratio of 2.60 and a beta of 0.77.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.51 by $0.05. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. The firm had revenue of $3.86 billion for the quarter, compared to analyst estimates of $3.68 billion. As a group, research analysts forecast that Boston Scientific Co. will post 2.32 EPS for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, Director Charles J. Dockendorff sold 3,946 shares of the stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $72.70, for a total transaction of $286,874.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Boston Scientific news, EVP Eric Francis Yves Thepaut sold 12,931 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $74.14, for a total transaction of $958,704.34. Following the transaction, the executive vice president now directly owns 31,422 shares in the company, valued at approximately $2,329,627.08. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Charles J. Dockendorff sold 3,946 shares of the company’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $72.70, for a total transaction of $286,874.20. The disclosure for this sale can be found here. Insiders have sold a total of 67,616 shares of company stock valued at $4,819,057 in the last 90 days. 0.50% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.